Eli Lilly and Company (LLY) analysis

Loading the Vaultflake…

Health is the lab's cash, not the hospital's. Quality separates the sale that repeats from a year of heavy demand that may not. Growth follows patients and the price the payer accepts, not a factory described here. P/E is read against a year of heavy demand, not against that year as normal. Shareholder return, if any, has to fit after development. Do not call it the largest market value in the sector.

The P/E of a year of heavy demand is not the earnings if the payer squeezes the price. EV/EBITDA is read without treating idle capacity as a cost that does not return. Do not use Novo Nordisk's multiple as if the two portfolios were the same book. A dash if LLY is missing.

Limits of this report

Not advice on Eli Lilly. Vaultflake does not describe manufacturing or administration, and does not treat the patent as a closed barrier. Read the filings. The table is a snapshot, not a target price.

Questions from this report